Report cover image

Hypovolemia - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18679654

Description

Hypovolemia - Pipeline Insight, 2024



DelveInsight’s, “Hypovolemia – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypovolemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Hypovolemia Understanding

Hypovolemia: Overview

Hypovolemia is a state of an abnormally decreased volume of circulating fluid (plasma) in the body. It may be caused by a rapid and substantial loss of blood or from dehydration due to vomiting, diarrhea, burns, severe environmental fluid losses, or drugs such as diuretics. Lost fluid in patients with dehydration is comprised primarily of plasma rather than whole blood as in the trauma patient.

Symptoms

Hypovolemia can be recognized by an elevated pulse, a diminished blood pressure, and the absence of perfusion as assessed through skin signs (skin turning pale) and/or capillary refill on forehead, lips and nail beds. The patient may feel dizzy, faint, nauseated, or very thirsty.

Diagnosis

Agoraphobia is diagnosed based on symptoms and signs a diagnosis. To be diagnosed with agoraphobia, symptoms need to meet certain criteria listed in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM). The DSM is a manual often used by healthcare providers to diagnose mental health conditions.

Treatment

Psychotherapy, involves meeting with a therapist or other mental health professional on a regular basis to talk about fears and any issues that may be contributing to fears. Cognitive behavioral therapy (CBT) is the most common form of psychotherapy used to treat people with agoraphobia. Certain medications are used to relieve agoraphobia or panic attack symptoms. These include selective serotonin reuptake inhibitors, such as paroxetine (Paxil) or fluoxetine (Prozac), selective serotonin and norepinephrine reuptake inhibitors, such as venlafaxine (Effexor) or duloxetine (Cymbalta), tricyclic antidepressants, such as amitriptyline (Elavil) or nortriptyline (Pamelor), anti-anxiety medications, such as alprazolam (Xanax) or clonazepam (Klonopin).

Hypovolemia Emerging Drugs Chapters

This segment of the Hypovolemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypovolemia Emerging Drugs
  • VBI-S: Vivacelle Bio
VBI-S is in Phase 2 of clinical trial study and is being developed by Vivacelle Bio. The trail got initiated in February 2021 and is expected to get completed by December 2021 with 20 expected enrolled participants.

Further product details are provided in the report……..

Hypovolemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypovolemia drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Hypovolemia
There are approx. 10+ key companies which are developing the therapies for Hypovolemia. The companies which have their Hypovolemia drug candidates in the most advanced stage, i.e. phase II include, Vivacelle Bio.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Hypovolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypovolemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypovolemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypovolemia drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hypovolemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypovolemia.
Hypovolemia Report Insights
  • Hypovolemia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Hypovolemia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Hypovolemia drugs?
  • How many Hypovolemia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypovolemia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypovolemia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypovolemia and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Vivacelle Bio
Key Products
  • VBI-S

Table of Contents

50 Pages
Introduction
Executive Summary
Hypovolemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypovolemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hypovolemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hypovolemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
VBI-S: Vivacelle Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Hypovolemia Key Companies
Hypovolemia Key Products
Hypovolemia- Unmet Needs
Hypovolemia- Market Drivers and Barriers
Hypovolemia- Future Perspectives and Conclusion
Hypovolemia Analyst Views
Hypovolemia Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us